A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Neuropathy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2014
At a glance
- Drugs GRC 17536 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 08 Sep 2012 Status changed from recruiting to withdrawn prior to recruitment in the United Kingdom. The trial has been completed in Germany.
- 31 Mar 2012 New source identified and integrated (European Clinical Trials Database record).
- 31 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.